Angelo Belotti

2.6k total citations
41 papers, 451 citations indexed

About

Angelo Belotti is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Angelo Belotti has authored 41 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 18 papers in Molecular Biology and 17 papers in Oncology. Recurrent topics in Angelo Belotti's work include Multiple Myeloma Research and Treatments (31 papers), Protein Degradation and Inhibitors (9 papers) and Acute Myeloid Leukemia Research (8 papers). Angelo Belotti is often cited by papers focused on Multiple Myeloma Research and Treatments (31 papers), Protein Degradation and Inhibitors (9 papers) and Acute Myeloid Leukemia Research (8 papers). Angelo Belotti collaborates with scholars based in Italy, United States and Spain. Angelo Belotti's co-authors include Giuseppe Rossi, Pietro Pioltelli, Rossella Ribolla, Mario Boccadoro, Enrico Maria Pogliani, Elena Maria Elli, Alessandra Tucci, Chiara Cattaneo, Valeria Cancelli and Marco Metra and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Angelo Belotti

36 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Angelo Belotti Italy	14	312	245	201	82	55	41	451
Yogesh Jethava United States	10	249 0.8×	206 0.8×	151 0.8×	53 0.6×	38 0.7×	50	423
Thomas G Martin United States	10	369 1.2×	318 1.3×	263 1.3×	36 0.4×	25 0.5×	19	504
Danai Dima United States	12	180 0.6×	170 0.7×	233 1.2×	40 0.5×	56 1.0×	69	409
Christy Samaras United States	13	264 0.8×	302 1.2×	189 0.9×	97 1.2×	16 0.3×	57	437
E. Klumper Netherlands	11	238 0.8×	228 0.9×	191 1.0×	51 0.6×	12 0.2×	19	590
Stephen J. Harding United Kingdom	11	230 0.7×	236 1.0×	73 0.4×	75 0.9×	26 0.5×	18	405
Michelle E. Maglio United States	8	215 0.7×	188 0.8×	149 0.7×	33 0.4×	13 0.2×	9	359
S Kulkarni United Kingdom	18	692 2.2×	256 1.0×	334 1.7×	104 1.3×	36 0.7×	32	810
Maciej Kaźmierczak Poland	13	194 0.6×	161 0.7×	90 0.4×	93 1.1×	102 1.9×	41	475
Mariella Grasso Italy	11	413 1.3×	330 1.3×	249 1.2×	79 1.0×	51 0.9×	29	539

Countries citing papers authored by Angelo Belotti

Since Specialization

Citations

This map shows the geographic impact of Angelo Belotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo Belotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo Belotti more than expected).

Fields of papers citing papers by Angelo Belotti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo Belotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo Belotti. The network helps show where Angelo Belotti may publish in the future.

Co-authorship network of co-authors of Angelo Belotti

This figure shows the co-authorship network connecting the top 25 collaborators of Angelo Belotti. A scholar is included among the top collaborators of Angelo Belotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo Belotti. Angelo Belotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Belotti, Angelo, Barbara Frittoli, Rossella Ribolla, et al.. (2025). Early identification of functional high-risk multiple myeloma patients after transplant: the predictive power of fat fraction and Response Assessment Category score in diffusion-weighted whole-body magnetic resonance imaging. Haematologica. 110(9). 2151–2159.

Fazio, Francesca, Maria Teresa Petrucci, Laura Corvatta, et al.. (2024). Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy. SHILAP Revista de lepidopterología. 5(3). 485–493. 1 indexed citations

Guerini, Andrea Emanuele, Paolo Borghetti, Luca Triggiani, et al.. (2024). Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma. Advances in Radiation Oncology. 10(3). 101696–101696.

Belotti, Angelo, Barbara Frittoli, Rossella Ribolla, et al.. (2024). Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score. Blood. 144(Supplement 1). 82–82. 1 indexed citations

Belotti, Angelo, Rossella Ribolla, Claudia Crippa, et al.. (2023). Predictive role of sustained imaging MRD negativity assessed by diffusion‐weighted whole‐body MRI in multiple myeloma. American Journal of Hematology. 98(9). E230–E232. 5 indexed citations

Guerini, Andrea Emanuele, Alessandra Tucci, Filippo Alongi, et al.. (2022). RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment. Cancers. 14(9). 2273–2273. 4 indexed citations

Bertoli, Diego, Chiara Cattaneo, Camillo Almici, et al.. (2022). The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. Annals of Hematology. 101(6). 1227–1237. 11 indexed citations

Belotti, Angelo, Rossella Ribolla, Claudia Crippa, et al.. (2022). Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy. Blood. 140(Supplement 1). 1140–1141. 2 indexed citations

Gay, Francesca, Roberto Mina, Delia Rota‐Scalabrini, et al.. (2021). Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.. Journal of Clinical Oncology. 39(15_suppl). 8002–8002. 19 indexed citations

10.

Ronca, Roberto, Gaia C. Ghedini, Federica Maccarinelli, et al.. (2020). FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation–Induced Mitochondrial Oxidative Stress. Cancer Research. 80(11). 2340–2354. 43 indexed citations

11.

Gay, Francesca, Pellegrino Musto, Delia Rota Scalabrini, et al.. (2020). Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. Blood. 136(Supplement 1). 35–37. 32 indexed citations

12.

Bringhen, Sara, Roberto Mina, Anna Maria Cafro, et al.. (2018). Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia. 32(8). 1803–1807. 34 indexed citations

13.

Gavazzoni, Mara, Enrico Vizzardi, Elio Gorga, et al.. (2018). Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence. European Journal of Pharmacology. 828. 80–88. 35 indexed citations

14.

Gavazzoni, Mara, Carlo Lombardi, Enrico Vizzardi, et al.. (2018). Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. European Journal of Pharmacology. 838. 85–90. 14 indexed citations

15.

Bringhen, Sara, Valeria Magarotto, Anna Marina Liberati, et al.. (2016). A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. Blood. 128(22). 1145–1145. 7 indexed citations

16.

Parma, Matteo, A Colombo, Federica Mottadelli, et al.. (2015). GOOD OUTCOME FOR VERY HIGH RISK ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA CARRYING GENETIC ABNORMALITIES t(4;11)(q21;q23) or t(9;22)(q34;q11), IF PROMPTLY SUBMITTED TO ALLOGENEIC TRANSPLANTATION, AFTER OBTAINING A GOOD MOLECULAR REMISSION.. Mediterranean Journal of Hematology and Infectious Diseases. 7(1). e2015041–e2015041. 2 indexed citations

17.

Belotti, Angelo, Lorena Duca, Lorenza Borin, et al.. (2014). Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications. Leukemia Research. 39(1). 88–91. 19 indexed citations

18.

Elli, Elena Maria, Angelo Belotti, Andrea Aroldi, et al.. (2014). IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS. Mediterranean Journal of Hematology and Infectious Diseases. 6(1). e2014042–e2014042. 12 indexed citations

19.

Elli, Elena Maria, et al.. (2012). A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management. Mediterranean Journal of Hematology and Infectious Diseases. 4(1). e2012017–e2012017.

20.

Belotti, Angelo, et al.. (2011). Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146⁺ immunomagnetic enrichment—flow cytometry and soluble E‐selectin detection. American Journal of Hematology. 87(3). 319–320. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact